Home Featured Page 10

Featured

Latest

Two Years After Rejection, Resilient Quietly Refiles MDMA for PTSD Application

Smooth Sailing: Definium’s LSD Voyage Hits Primary and Key Secondary Endpoints in GAD

Weekly Psychedelic Policy Briefing – August 9, 2026

Ibogaine’s Moment Has Arrived. Are We Ready to Meet It?

The Post-Psychedelic Challenges Study: A Vital New Frontier in Psychedelic Science

March 2026 Psychedelic Bill Round-up

Ketamine-Assisted Couple Therapy Training by Enamory

Serotonin, Synapses, and Setting: Gitte Moos Knudsen on the Neurobiology of...

The Psychedelic Writers Guild’s Denver Mixer

The Mushroom Cure – Special Live Filming

Pα+ Psychedelic Bulletin #222: Unpacking EPIsoDE; Meta-Analysis Says Psychedelics No Better...

BREAKING: Otsuka to Acquire Methylone Drug Developer Transcend in $1.23B Deal

Esme Dark – Psychedelics, Somatics and the Shadow

What Approval Won’t Solve: Brian Barnett on Ketamine’s Lessons, RVUs, and...

EDITOR PICKS

Two Years After Rejection, Resilient Quietly Refiles MDMA for PTSD Application

Smooth Sailing: Definium’s LSD Voyage Hits Primary and Key Secondary Endpoints...

Weekly Psychedelic Policy Briefing – August 9, 2026

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

Two Years After Rejection, Resilient Quietly Refiles MDMA for PTSD Application

Smooth Sailing: Definium’s LSD Voyage Hits Primary and Key Secondary Endpoints in GAD

Weekly Psychedelic Policy Briefing – August 9, 2026

Ibogaine’s Moment Has Arrived. Are We Ready to Meet It?

The Post-Psychedelic Challenges Study: A Vital New Frontier in Psychedelic Science

March 2026 Psychedelic Bill Round-up

Ketamine-Assisted Couple Therapy Training by Enamory

Quarterly Briefing: Q1 2026

Serotonin, Synapses, and Setting: Gitte Moos Knudsen on the Neurobiology of...

The Psychedelic Writers Guild’s Denver Mixer

The Mushroom Cure – Special Live Filming

Pα+ Psychedelic Bulletin #222: Unpacking EPIsoDE; Meta-Analysis Says Psychedelics No Better...

BREAKING: Otsuka to Acquire Methylone Drug Developer Transcend in $1.23B Deal

Esme Dark – Psychedelics, Somatics and the Shadow

What Approval Won’t Solve: Brian Barnett on Ketamine’s Lessons, RVUs, and...

EDITOR PICKS

Two Years After Rejection, Resilient Quietly Refiles MDMA for PTSD Application

Smooth Sailing: Definium’s LSD Voyage Hits Primary and Key Secondary Endpoints...

Weekly Psychedelic Policy Briefing – August 9, 2026

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY